A phase II, randomized trial of open-label Truvada [emtricitabine/tenofovir-disoproxil-fumarate] with atazanavir/ritonavir versus multi-class therapy with Truvada, atazanavir/ritonavir, maraviroc and raltegravir in acutely HIV-1 infected antiretroviral-naive subjects.

Trial Profile

A phase II, randomized trial of open-label Truvada [emtricitabine/tenofovir-disoproxil-fumarate] with atazanavir/ritonavir versus multi-class therapy with Truvada, atazanavir/ritonavir, maraviroc and raltegravir in acutely HIV-1 infected antiretroviral-naive subjects.

Completed
Phase of Trial: Phase II

Latest Information Update: 16 Mar 2015

At a glance

  • Drugs Maraviroc (Primary) ; Raltegravir (Primary) ; Darunavir; Emtricitabine/tenofovir disoproxil fumarate; Ritonavir
  • Indications HIV-1 infections
  • Focus Therapeutic Use
  • Most Recent Events

    • 01 May 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 12 Oct 2011 Planned end date changed from 1 Dec 2010 to 1 Dec 2011 as reported by ClinicalTrials.gov.
    • 24 May 2010 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top